Evidence map›Paper›PMID 38164579›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024

[

David L Chan, Aimee R Hayes, Ioannis Karfis, Alice Conner, Magdalena Mileva, Elizabeth Bernard, Geoffrey Schembri, Shaunak Navalkissoor, Gopinath Gnanasegaran, Nick Pavlakis and 7 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Prognostic impact of discordant lesions on [Frontiers in nuclear medicine · 2026
    Article
  7. Review
  8. The utility ofThyroid research · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Research process of PET tracers for neuroendocrine tumors diagnosis.American journal of nuclear medicine and molecular imaging · 2025
    Review
  13. [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

David L ChanFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; david.chan@sydney.edu.au.
Aimee R HayesNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom.
Ioannis KarfisNuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Alice ConnerFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Magdalena MilevaNuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Elizabeth BernardNuclear Medicine, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Geoffrey SchembriNuclear Medicine, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Shaunak NavalkissoorNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom.
Gopinath GnanasegaranNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom.
Nick PavlakisFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Clémentine MarinNuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Bruno VanderlindenMedical Physics Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Patrick FlamenNuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Paul RoachNuclear Medicine, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Martyn E CaplinNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom.
Christos ToumpanakisNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom.
Dale L BaileyFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Royal North Shore Hospital · AUInstitut Jules Bordet · BEUniversity College London · GBThe Royal Free Hospital · GBThe University of Sydney · AUUniversité Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[

Indexed as

Gastrointestinal NeoplasmsNeuroendocrine TumorsOrganometallic CompoundsBiomarkersFemaleFluorodeoxyglucose F18Gallium RadioisotopesHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyRetrospective StudiesBiomarkersFluorodeoxyglucose F18Gallium RadioisotopesOrganometallic Compounds[18F]FDGdiscordancedual PETprognostic biomarkertumor volume

Identifiers

PMID38164579
PMCPMC10858377
OpenAlexW4390048079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.